Cadrenal Therapeutics Inc. (NASDAQ: CVKD)
$16.0600
-0.1100 ( -0.47% ) 0.0K
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Market Data
Open
$16.0600
Previous close
$16.1700
Volume
0.0K
Market cap
$26.82M
Day range
$16.1350 - $16.1350
52 week range
$5.4000 - $32.5500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Aug 06, 2024 |
8-k | 8K-related | 14 | Jul 31, 2024 |
ars | Annual reports | 1 | Jun 11, 2024 |
def | Proxies and info statements | 5 | Jun 11, 2024 |
pre | Proxies and info statements | 3 | May 29, 2024 |
8-k | 8K-related | 13 | May 09, 2024 |
10-q | Quarterly Reports | 59 | May 09, 2024 |
4 | Insider transactions | 1 | Apr 10, 2024 |
8-k | 8K-related | 14 | Apr 09, 2024 |
3 | Insider transactions | 2 | Apr 03, 2024 |